At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 (Ezabenlimab) Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
In Brief
A Phase 2 clinical trial evaluating Ezabenlimab, BI 754111, and 1 other intervention for Neoplasm Metastasis and 2 related conditions. Completed, enrolled 211 participants across 17 sites in 3 countries.
Detailed Summary
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.
Study Details
Timeline
Interventions
240 mg of ezabenlimab (BI 754091), intravenously, on Day 1 of 21-day cycles.
600 mg of BI 754111, intravenously, on Day 1 of 21-day cycles.
720 mg of BI 836880, intravenously, on Day 1 of 21-day cycles.